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Abstract 26 
Trough gentamicin therapeutic drug monitoring (TDM) is time-consuming, disruptive to neonatal 27 
clinical care and a patient safety issue. Bayesian models could allow TDM to be performed 28 
opportunistically at the time of routine blood tests. This study aimed to develop and prospectively 29 
evaluate a new gentamicin model and a novel Bayesian computer tool (neoGent) for TDM use in 30 
neonatal intensive care. We also evaluated model performance for predicting peak concentrations and 31 
AUC(0-t). A pharmacokinetic meta-analysis was performed on pooled data from three studies (1325 32 
concentrations from 205 patients). A 3-compartment model was used with covariates being: 33 
allometric weight scaling, postmenstrual and postnatal age, and serum creatinine. Final parameter 34 
estimates (standard error) were: clearance: 6.2 (0.3) L/h/70kg; central volume (V) 26.5 (0.6) L/70kg; 35 
inter-compartmental disposition: Q=2.2 (0.3) L/h/70kg, V2=21.2 (1.5) L/70kg, Q2=0.3 (0.05) 36 
L/h/70kg, V3=148 (52.0) L/70kg. The model’s ability to predict trough concentrations from an 37 
opportunistic sample was evaluated in a prospective observational cohort study that included data 38 
from 163 patients with 483 concentrations collected in five hospitals. Unbiased trough predictions 39 
were obtained: median (95% confidence interval (CI)) prediction error was 0.0004 (-1.07, 0.84) mg/L. 40 
Results also showed peaks and AUC(0-t) could be predicted (from one randomly selected sample) 41 
with little bias but relative imprecision with median (95% CI) prediction error being 0.16 (-4.76, 5.01) 42 
mg/L and 10.8 (-24.9, 62.2) mg h/L, respectively. NeoGent was implemented in R/NONMEM, and in 43 
the freely available TDMx software. 44 
  45 
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Introduction 46 
The aminoglycoside antibiotic gentamicin is the most commonly used antimicrobial on neonatal 47 
units(1, 2) and is effective against Gram negative bacteria. Gentamicin use is limited by its narrow 48 
therapeutic index and risk of toxicity, specifically nephro- and ototoxicity(3). It is not metabolized in 49 
the liver(4) and is almost entirely eliminated by the kidneys; clearance therefore depends on renal 50 
function. During the first two weeks of life, renal and intra-renal blood flow increase rapidly, causing 51 
a steep rise in glomerular filtration rate (GFR)(5, 6). 52 
Therapeutic drug monitoring (TDM) is required to ensure maximal efficacy and especially minimal 53 
toxicity, particularly in the neonatal population where variability in pharmacokinetic (PK) parameters 54 
is large. Dose individualization approaches focus on toxicity(7, 8) and include single-level methods 55 
and nomograms(9, 10), area under the curve (AUC) methods(11), and Bayesian methods(12). The use 56 
of nomograms is limited as they cannot readily incorporate covariates affecting PK parameters. AUC 57 
methods use a simplified 1-compartment PK model and require at least two gentamicin 58 
measurements, which is not appropriate in neonates with limited blood volumes. These drawbacks 59 
make Bayesian approaches the most attractive for newborn infants. 60 
Deriving a Bayesian prior for TDM requires a non-linear mixed-effect PK model, and several such 61 
studies of neonatal gentamicin have been published(13-24). However, these studies are limited by 62 
their heterogeneity and use of sparse data (often identifying only a 1-compartment model when 63 
gentamicin follows multi-compartment kinetics(25, 26)) and fail to account for age-related differences 64 
in creatinine during the immediate newborn period. Although gentamicin is not a new drug, its dosing 65 
and monitoring is still a current issue as identified in the UK National Patient Safety alert 66 
(http://www.nrls.npsa.nhs.uk/alerts/?entryid45=66271) and a recent publication by Valitalo et al(27), 67 
who used simulations to define dosing guidelines. 68 
We aimed to investigate whether opportunistic sampling can predict trough gentamicin concentrations 69 
so that standard TDM could be performed from a blood sample taken for other purposes (e.g. routine 70 
blood gases). As a secondary aim, we evaluated the model’s ability to predict peak gentamicin 71 
concentrations and AUC(0-t) using one randomly selected sample.   72 
4 
 
Methods 73 
Study population 74 
This study used two datasets: a model-building dataset and a prospectively collected evaluation 75 
dataset.  76 
To collect data for model development, the electronic bibliographic database PubMed was searched in 77 
January 2015 without time limitations. The search strategy included: (neonat* OR newborn*) AND 78 
(gentamicin) AND (pharmacokinetic* OR PK); gentamicin samples had to be prospectively collected 79 
and covariates (weight, gestational age (GA), postnatal age (PNA), serum creatinine measurements), 80 
also had to be reported. Additionally, we also searched the reference lists in identified papers. The 81 
authors of the publications that met the inclusion criteria (n=8) (11, 15, 21, 22, 28-31) were then 82 
invited to contribute their data.  83 
Data for the evaluation of the PK model were collected as a prospective observational cohort study 84 
from five UK hospitals (St George's University Hospitals NHS Foundation Trust, Liverpool Women's 85 
NHS Foundation Trust, Oxford University Hospitals, Portsmouth Hospitals NHS Trust and Coventry 86 
& Warwickshire University Hospitals NHS Trust) from July 2012 to November 2013. Infants were 87 
eligible for inclusion if the following criteria were met: more than 36 hours gentamicin therapy 88 
anticipated, postnatal age of less than 90 days, not receiving extracorporeal membrane oxygenation, 89 
peritoneal dialysis or hemofiltration, and expected to survive the study period (as judged by the 90 
clinical team). Each patient provided a minimum of two gentamicin concentrations – a trough sample 91 
from routine TDM (i.e. a pre-dose sample taken before a non-initial dose) and an additional study 92 
sample (taken opportunistically during a course of gentamicin when the infant required blood 93 
sampling for clinical care). These samples will be referred to as routine (trough) and (opportunistic) 94 
study samples in this manuscript. Exact times of gentamicin dosing and sampling were recorded, 95 
along with the patient’s weight, age and serum creatinine (Table 1). Written informed consent was 96 
obtained from parents and the study was approved by the London Central Ethics committee (reference 97 
12/LO/0455). 98 
 99 
Gentamicin dosing and sampling procedure in the prospective evaluation dataset 100 
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Gentamicin treatment was initiated at the discretion of the clinical team for possible infection and 101 
dosed and monitored using trough concentrations according to the standard practice at each hospital. 102 
Gentamicin was administered as a slow (<2 min) bolus via intravenous cannula, percutaneous long 103 
line, or umbilical venous catheter. 104 
 105 
Bioanalytical techniques 106 
An enzyme immunoassay (EMIT, Syva)(15), a fluorescence polarization immunoassay (TDx, 107 
Abbot)(15, 21), and high performance liquid chromatography coupled to tandem mass spectrometry 108 
(UHPLC-MS/MS) (32) were used to determine gentamicin concentration in the model-building 109 
dataset; and the Jaffe reaction (33) was used to determine serum creatinine concentrations. In the 110 
prospective evaluation dataset, gentamicin serum concentrations were analyzed using immunoassay 111 
techniques (Table S1); and creatinine concentrations were determined by either a Jaffe-based or an 112 
enzymatic method (137 neonates and 26 neonates, respectively). 113 
 114 
Pharmacokinetic analysis 115 
The observed concentration-time data from only the model-building studies were pooled and 116 
simultaneously analyzed with non-linear mixed-effects software NONMEM version 7.3(34). The first 117 
order conditional estimation method with interaction was used.  118 
 119 
Basic model 120 
One-, 2-, and 3-compartment structural models were considered when defining the basic structural 121 
population PK model. The inter-individual variability (IIV) was assumed to follow a log-normal 122 
distribution and tested on all parameters. An additive, a proportional, and a combination of both 123 
(Equation 1) residual error models were tested.  124 
𝑦𝑖𝑗 = 𝑓(𝑡𝑖𝑗;  𝜙𝑖) +  𝑓(𝑡𝑖𝑗;  𝜙𝑖) ∙  𝜀𝑖𝑗(𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛𝑎𝑙) +  𝜀𝑖𝑗(𝑎𝑑𝑑𝑖𝑡𝑖𝑣𝑒),    (Equation 1) 125 
where yij is an observed gentamicin concentration at time tij, f is the function that represents the 126 
gentamicin model, 𝜙𝑖 is a vector of parameters, εij is a residual error term. 127 
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Inter-occasion variability (IOV) was also assumed to be log-normally distributed and it was tested for 128 
all parameters with an occasion defined as a single dosing interval. 129 
 130 
Covariate model 131 
Allometric scaling was used a priori to standardize all PK parameters to 70 kg (35), and a maturation 132 
function, describing the maturation of the GFR with postmenstrual age (PMA) (Equation 2) with fixed 133 
parameters from a previous study (5), was used to scale clearance. Allometric exponents were fixed to 134 
0.632 for central clearance and 0.75 for inter-compartmental clearances. Different exponents were 135 
used because these values were shown best for describing the maturation of renal elimination(5) and 136 
tissue blood flows(36), respectively. Allometric exponents for volumes of distribution were fixed to 1. 137 
The combination of allometric weight scaling and sigmoidal maturation function was suggested as a 138 
standard method for scaling clearance in the pediatric population in a recent comparison of different 139 
approaches(37). 140 
𝑚𝑎𝑡𝑢𝑟𝑎𝑡𝑖𝑜𝑛 𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛 =  
𝑃𝑀𝐴𝐻𝑖𝑙𝑙
𝑃𝑀𝐴50
𝐻𝑖𝑙𝑙+𝑃𝑀𝐴𝐻𝑖𝑙𝑙
,      (Equation 2) 141 
where Hill is the sigmoidicity coefficient and PMA50 is PMA when maturation of GFR reaches 50% 142 
of adult values. 143 
As it is known that PNA and serum creatinine are important indicators of gentamicin clearance and 144 
also based on the posthoc estimates of etas versus covariates plots, they were tested on clearance. 145 
These time-varying covariates were considered to significantly improve the fit and therefore included 146 
in the model if the difference in objective function value (ΔOFV) after their inclusion was >3.84 147 
(p<0.05). Additionally, linear extrapolations between observations were made. To account for 148 
endogenous creatinine, maternal creatinine and also the change in renal function with age, a typical 149 
value of serum creatinine (TSCr) for a specific PMA was determined using data from Cuzzolin et 150 
al(38) for preterm (GA<37 weeks) newborns and Rudd et al(39) for term newborns. A linear decline 151 
in TSCr with increasing PMA was found according to Equation 3:  152 
𝑇𝑆𝐶𝑟 =  −2.849 ∙ 𝑃𝑀𝐴 (𝑤𝑒𝑒𝑘𝑠) + 166.48.      (Equation 3) 153 
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A possible influence of serum creatinine on clearance was tested according to the following Equation 154 
4, where measured serum creatinine (MSCr) was standardized by TSCr for PMA and departures from 155 
it estimated as follows: 156 
(
𝑀𝑆𝐶𝑟
𝑇𝑆𝐶𝑟
)
θ
.          (Equation 4) 157 
The effect of PNA was investigated with a logistic function (Equation 5) to account for the rapid 158 
changes in gentamicin clearance in the first hours of life. The first day of life was defined as day 1. 159 
𝑝𝑜𝑠𝑡𝑛𝑎𝑡𝑎𝑙 𝑎𝑔𝑒 𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛 =  
𝑃𝑁𝐴
𝑃𝑁𝐴50+𝑃𝑁𝐴
,      (Equation 5) 160 
where PNA50 is the PNA when clearance has reached 50% of typical adult's clearance. 161 
After the forward selection (ΔOFV>3.84) of all covariates (full model), backward elimination was 162 
performed, with a p-value retention cut-off of 0.001 (ΔOFV<10.83). 163 
 164 
Evaluation 165 
Internal model evaluation 166 
Basic goodness-of-fit plots for observations versus population and individual predictions, conditional 167 
weighted residuals versus population predictions and versus time after dose were produced using 168 
statistical software R version 3.1.0 (R Core Team (2014). R: A language and environment for 169 
statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from: 170 
http://www.R-project.org/) and visually examined. The assumptions of normality and homogeneity of 171 
the residuals errors were investigated by inspecting a histogram and a qq-plot. 172 
Standard errors from NONMEM covariance step and non-parametric bootstrap analysis with 1,000 173 
replicates were used to determine the precision of the final PK parameter estimates.  174 
Additionally, we simulated 1,000 datasets using parameter estimates from the final model, and plotted 175 
95% confidence intervals (CI) around the 2.5th, 50th, and 97.5th prediction percentiles of the simulated 176 
data. Then, the observations were overlaid on the plot, also called the visual predictive check (VPC). 177 
Perl-speaks-NONMEM (PsN) software(40) was used for the bootstrap analysis and to produce the 178 
VPC, which was visualized using R-package Xpose4(41). 179 
 180 
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External model evaluation 181 
The prospective evaluation dataset was used to evaluate the predictive performance of the model. No 182 
additional fitting was done, and the diagnostic plots and the VPC were generated as described above. 183 
Bayesian model-predicted trough concentrations were computed using the model as a prior and 184 
information from only the opportunistic study samples. These predictions were compared with the 185 
observed trough concentrations by calculating the prediction error (PE) (42), and also the mean PE 186 
(MPE) (i.e. a measure of bias), and root-mean-square error (RMSE), a measure of precision(43) 187 
(Equations 6). 188 
𝑃𝐸 = 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 − 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑      189 
𝑀𝑃𝐸 =
1
𝑁
∙ ∑ ∙ 𝑃𝐸𝑖
𝑁
𝑖=1         (Equations 6) 190 
𝑅𝑀𝑆𝐸 = √
1
𝑁
∙ ∑∙ 𝑃𝐸𝑖
2
𝑁
𝑖=1
 191 
Also, we counted the number of “correct” predictions that were below or above the currently 192 
recommended gentamicin trough concentration thresholds of 1 mg/L or 2 mg/L (the National Institute 193 
for Health and Care Excellence (NICE) (http://www.nice.org.uk/guidance/CG149/chapter/1-194 
Guidance#therapeutic-drug-monitoring-for-gentamicin) and British National Formulary for Children 195 
(BNFc) (http://www.evidence.nhs.uk/formulary/bnfc/current/5-infections/51-antibacterial-drugs/514-196 
aminoglycosides/gentamicin)). 197 
Further analysis of paired samples (that is both study and routine samples taken in the same dosing 198 
interval) was undertaken for the following scenarios: study samples ≥1, ≥2, and ≥3 mg/L, compared 199 
with only unpaired samples. 200 
 201 
Cross-validation 202 
The subset with the study sample above 3 mg/L provided the most important comparison, since in this 203 
case the study sample was still above the pre-specified trough threshold. As there were only 18 pairs 204 
with opportunistic study concentration ≥3 mg/L in the evaluation dataset, these pairs were merged 205 
with paired samples of the same characteristics from the model-building dataset. The pooled dataset 206 
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was then randomly split into five subsets, and cross-validation was performed; meaning that in each 207 
subset 20% of the pairs were randomly removed and the model was re-estimated. The re-estimated 208 
model was then used as a prior to predict the troughs, and compared to the observed trough 209 
concentrations as previously described. 210 
Whether the model is able to predict peak concentrations from one randomly selected non-peak 211 
sample was tested similarly as described above, using paired samples from both the model-building 212 
and the evaluation dataset, and performing cross-validations. Additionally, as a possible 213 
pharmacokinetic-pharmacodynamic target for aminoglycosides can also be AUC(0-24)/MIC (44), the 214 
model was also evaluated on how it predicts AUC(0-t). Only a subset of the data where five or more 215 
samples were collected after the same dose was used for defining AUC(0-t), and the model-predicted 216 
versus observed (non-compartmental) AUC(0-t) was compared. 217 
 218 
Comparison with other models 219 
To compare our mechanistic model which scales for size, age and expected renal function with 220 
previously published models using empirical covariate analysis, predictions for the measured trough 221 
from the routine opportunistic samples in our prospective dataset were generated.  222 
 223 
neoGent software 224 
The model was implemented using R and NONMEM (see Supplementary material).  It works by 225 
reading an individual’s data into R, then Bayesian estimates generated in NONMEM are used to 226 
predict outcomes of interest (e.g. the time when the concentration falls below 2 mg/L). 227 
 228 
  229 
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Results 230 
Patients 231 
Out of eight contacted authors identified in the literature search we obtained two large neonatal 232 
gentamicin datasets (15, 21).  We received no response from four authors (11, 28-30); and although an 233 
initial response was received from two authors (22, 31) no data were actually shared. Additionally, we 234 
obtained some previously unpublished data taken during a PK study of ampicillin and penicillin (32). 235 
The data were pooled and comprised 1325 gentamicin concentrations from 205 neonates (Table 1). 236 
This dataset was used to derive the model. 237 
For the model evaluation, gentamicin serum concentrations were prospectively collected from a total 238 
of 194 neonates. Of the enrolled patients, 163 were included in the PK analysis (Table 1). Reasons for 239 
exclusion (31 patients) included inexact sampling times, insufficient samples, or the gentamicin 240 
opportunistic study concentration being below the limit of quantification (n=12). The final evaluation 241 
dataset comprised 483 gentamicin serum measurements, with 229 study and 254 routinely taken 242 
trough concentrations. Median (range) time after dose was 13.3 (0.08-53.3) h and 31.1 (8.0-79.7) h for 243 
study and routine concentrations, respectively. Patients were on treatment for up to 20 days. 244 
 245 
Pharmacokinetic analysis 246 
Initially, a 2-compartment model provided a better fit to the data (ΔOFV=7.4 with a 3-compartment 247 
model) and was therefore chosen as the basic structural model. But, after the addition of the fixed 248 
allometric and renal function parameters, covariates and IOV, a 3-compartment model described the 249 
data better (47-unit drop in OFV). The IIV was described with an exponential error structure, and the 250 
best residual error model was a combination of a proportional and additive error.  251 
Postnatal age and standardized serum creatinine had a significant effect on clearance (ΔOFV=134.1 252 
and ΔOFV=17.2, respectively) and were thus included in the final model. Backward elimination 253 
(p=0.001) confirmed that these covariates remained significant with the 3-compartment model. The 254 
final gentamicin population PK model is summarized with Equations 7. 255 
𝐶𝐿 =  𝜃𝐶𝐿 ∙ (
𝑊𝑇
70
)
0.632
∙
𝑃𝑀𝐴3.33
55.43.33+𝑃𝑀𝐴3.33
∙ (
𝑀𝑆𝐶𝑟
𝑇𝑆𝐶𝑟
)
𝜃𝑆𝐶𝑟
∙
𝑃𝑁𝐴
𝜃𝑃50+𝑃𝑁𝐴
∙ 𝑒(𝜂𝐶𝐿+𝜅𝐶𝐿), 256 
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𝑉 =  𝜃𝑉 ∙ (
𝑊𝑇
70
) ∙ 𝑒𝜂𝑉 ,         (Equations 7) 257 
𝑄 =  𝜃𝑄 ∙ (
𝑊𝑇
70
)
0.75
∙ 𝑒𝜂𝑄, 258 
 259 
where CL is gentamicin clearance, V is gentamicin volume of distribution, Q is inter-compartmental 260 
gentamicin clearance, WT is body weight in kilograms, η is IIV, κ is IOV. 261 
There was only a small improvement in fit (ΔOFV=7.6) when the model was parameterized for time-262 
varying covariates (linear extrapolation between observed covariate values), but as this model is more 263 
biologically plausible, it was chosen as the final model. 264 
The OFV reduced from 2305.0 to 1217.5 between the basic and the final model. The inclusion of the 265 
covariates resulted in a reduction of the IIV on PK parameters: with the basic model the IIV on CL 266 
and V was 71.1% and 62.5%, respectively, and with the final model, 41.8% and 33.5%, respectively. 267 
The final PK parameter estimates with uncertainty are reported in Table 2. 268 
 269 
Evaluation 270 
Internal model evaluation 271 
Figure 1 shows plots assessing goodness-of-fit by comparing observations and predictions. A VPC of 272 
the final model is shown in Figure 2.  273 
 274 
External model evaluation 275 
The basic diagnostic plots are presented in Figure 1, and the VPC performed using the evaluation 276 
dataset and the final parameters from the PK model without additional fitting in Figure 2. 277 
Table 3 shows the number of correct predictions (for five different datasets from the evaluation data 278 
and pooled results from the cross-validation) for gentamicin trough thresholds of 1 and 2 mg/L 279 
together with prediction errors. In the total dataset, containing both paired and unpaired samples, the 280 
median (95% CI) PE was 0.0004 (-1.1, 0.8) mg/L. The MPEs when predicting trough and peak 281 
concentrations (using cross-validations) were 0.03 and 0.19 mg/L; and the RMSE 1.28 and 2.55 mg/L, 282 
respectively (Table 3). When AUC(0-t) prediction (from one random sample) was evaluated, MPE 283 
was 14.5 mg h/L, and RMSE 30.2 mg h/L. 284 
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Figure 3 shows the median and the range of PE for this model and previously published gentamicin 285 
population PK models. 286 
 287 
NeoGent 288 
Figure S1 shows an example of output from neoGent. 289 
 290 
  291 
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Discussion 292 
A PK model for gentamicin in neonates was developed and evaluated with prospectively collected 293 
data. Through its use of mechanistic covariates the model gave unbiased predictions of trough 294 
concentration from an opportunistic sample. Using this model, concentrations from samples taken at 295 
any time can be used to generate informative TDM, potentially eliminating the need for specifically 296 
timed trough gentamicin samples and the safety concerns and inconvenience associated with them. An 297 
exploratory analysis to evaluate whether such an approach could be used for predicting individual 298 
peak concentration and AUC(0-t) showed that while predictions were unbiased, they were relatively 299 
imprecise (Table 3).  300 
 301 
The small median PE (0.0004 mg/L) for trough concentrations suggests that the model implemented 302 
in neoGent performs well, although some outliers were not captured (range: -2.4 – 1.6 mg/L). The 303 
median prediction errors were in most cases negative (Table 3), indicating that the model slightly 304 
over-predicts the trough concentrations (i.e. predicts them to be higher than they are), which might be 305 
(from a safety perspective) preferable to under-predicting. Cross-validations confirmed that samples 306 
do not need to be taken at a specific time when using this model for TDM, as predictions of trough 307 
concentrations (using an opportunistic sample) were unbiased, with median PE of -0.04 mg/L (Table 308 
3). Although we did not test the effect of the sampling time on model predictions; the samples were 309 
collected from a wide range of times (0.1-53.3 h after the dose), as they would be in routine hospital 310 
tests. 311 
 312 
Comparison of the developed model with the existing published models showed that the predicted 313 
trough concentrations were the least biased (i.e. the median prediction error was the smallest) when 314 
our model was used (Figure 3). However, due to unavailability of some covariates in our dataset, three 315 
models were used without all of the covariates (APGAR score(15, 19), sepsis(19), co-medication with 316 
dopamine(23)) included, which could explain their worse predictive performance. 317 
 318 
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The rich data in our model-building dataset (6.5 samples per patient) supported a 3-compartment 319 
model, where the final estimates for the third compartment were: inter-compartmental clearance 0.3 320 
L/h/70kg and peripheral volume of distribution of 148 L/70kg. Additionally, the terminal half-life for 321 
a typical subject from the prospective evaluation dataset (weight 2.0 kg, PMA 34.9 weeks, PNA 6 322 
days, MSCr 47.0 μmol/L, TSCr 66.4 μmol/L) was 189.7 hours. This could indicate uptake of 323 
gentamicin into the renal cortex, and slow excretion from it (45); and is in agreement with previously 324 
found evidence of deep tissue accumulation of gentamicin (26, 46).  325 
 326 
Unfortunately many authors were unwilling or unable to share their data and we only managed to 327 
obtain data from two (15, 21) out of eight identified studies for our model building dataset. We did 328 
obtain one further subsequent dataset where assays from another pharmacokinetic study in neonates 329 
also receiving gentamicin were used (32). Due to differences in model structure and parameterization, 330 
it was not possible to extract relevant information for model building from the published reports. 331 
However, in part because data from Nielsen et al(21) was of such high quality with multiple samples 332 
per patient, our final model described both model building and the evaluation datasets well, as shown 333 
in Figures 1 and 2. The histogram and the qq-plot of the conditional weighted residuals (data not 334 
shown) confirmed that they follow a normal distribution. The final estimates for clearance (CL) and 335 
volume of distribution (V) were (mean (standard error)) 6.21 (0.30) L/h/70 kg and 26.5 (1.11) L/70kg, 336 
respectively (Table 2). The values of the PK parameters for a typical infant from the model-building 337 
dataset (weight 2.12 kg, PMA 33.0 weeks, PNA 5.4 days, MSCr 78 μmol/L, TSCr 71.4 μmol/L) were 338 
0.077 L/h and 0.80 L (and 0.10 L/h and 0.78 L for a neonate from the evaluation dataset) for CL and 339 
V, respectively. These values are in agreement with estimates for clearance from previous neonatal 340 
studies of gentamicin pharmacokinetics(13, 14, 18, 22-24). The reported value for CL from Nielsen et 341 
al(21) may appear to be lower (0.026 L/h), but when our median demographic values were used in 342 
their model, the CL became similar to our estimates (0.095 L/h). The final estimate for volume of 343 
distribution is consistent with the estimate from Fuchs et al(23) and Botha et al(24), but it is not in 344 
accordance with what was found by Garcia et al (20) (0.252 L). The probable reason for this is a 345 
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different studied population, as when the median weight from our dataset was used in their model, the 346 
resulting V was 0.968 L, in agreement with our estimate.  347 
 348 
We did not attempt to estimate the allometric power exponents and constants of the maturation 349 
function as the PMA in the studied neonates (23.3-43.8 weeks) was insufficient to capture the age 350 
when maturation is complete (PMA50=55.4 weeks(5)); instead, these constants were fixed to the 351 
values from another study in which the main focus was renal maturation(5). This type of scaling was 352 
used to improve the model usefulness by allowing it to be extrapolated to different subpopulations 353 
(for example, neonates with a different weight, or PMA). In addition to changes in clearance due to 354 
long-term maturation that extends throughout gestation and into the first two years of life, we 355 
attempted to capture the short-term changes in clearance that occur after birth regardless of gestational 356 
age. A benefit of fixing the long-term maturation based on known relationships between PMA and 357 
renal function was that this short-term maturation was apparent with our estimate of PNA50 of 40.8 358 
hours, indicating that clearance rapidly increases over the first few days of life. In the first day of life 359 
the clearance was at 37% of the value for a typical adult, and it reached 95% by the end of the first 360 
month of age. 361 
 362 
The typical serum creatinine (used in the model) was determined using SCr concentrations, 363 
determined by the Jaffe assay, because the same method was used to determine SCr in the model-364 
building dataset. But to determine SCr in the evaluation dataset, assays, based on both the Jaffe and 365 
the enzymatic methods, were used. However, the goodness-of-fit to the evaluation dataset and the 366 
predictive performance of the model were good, therefore no correction factor was included. Also, the 367 
enzymatic assay was only used in 16% of patients. Due to the range of the data that was used to 368 
determine typical-for-PMA SCr the model can be used for a neonate with PMA <44 weeks or a term 369 
neonate of <4weeks of age. The power exponent on the creatinine function was estimated to be -0.13, 370 
meaning that if observed SCr and  typical SCr were70 μmol/L and 60 μmol/L, respectively, clearance 371 
would be 2% lower. 372 
 373 
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Large η-shrinkage indicates that the data do not contain enough information to make a reliable 374 
individual estimation. And whilst the shrinkage was large on the peripheral volumes of distribution 375 
(V2 and V3), it was relatively small on clearance (6.9%) (Table 2), which is important for making 376 
predictions of trough gentamicin concentrations and AUC(0-t). The η-shrinkage was also relatively 377 
small (15%) on the central volume of distribution (Table 2). 378 
 379 
Although the main aim was to evaluate whether the model can predict trough concentrations, the 380 
ability of the model to predict peak gentamicin concentration (from a randomly-selected non-peak 381 
sample) was also examined. Cross-validations showed that the median prediction error (95% CI) 382 
when predicting peaks was 0.16 (-4.76, 5.01) mg/L, indicating unbiased, but not very precise 383 
predictions. This is perhaps not surprising, given that concentrations collected at a median time after 384 
dose of 19.3 hours were used to predict concentrations at median 1h post dose. The prediction of 385 
AUC(0-t) (also from one sample) was similarly unbiased (median prediction error 10.8 mg h/L), but 386 
imprecise (95% CI: -24.9, 62.2 mg h/L) (Table 3). However, normalized RMSEs (by the range of 387 
observed data) for peak and AUC(0-t) prediction were 7.0% and 17.6%, respectively; indicating that 388 
considering the range of possible values, the precision is perhaps more acceptable. Target AUC(0-24) 389 
or peak values have not been defined in neonates, and slow clearance and a narrow therapeutic index 390 
mean that adjusting doses to target efficacy in this population may not be realistic. However, our 391 
model does now give unbiased predictions of both metrics from an opportunistically collected single 392 
sample, which should prove useful in future clinical research to define efficacy targets in this age 393 
group. At present, due to their imprecision, these predictions (for peak concentration and AUC(0-t)) 394 
should currently only be used for research purposes, and not for dose adjustment. 395 
 396 
Conclusion 397 
A new gentamicin model has been developed and evaluated with prospectively collected data. We 398 
used mechanistic covariate parameterization informed by principles of allometric size scaling, known 399 
scaling of glomerular filtration maturation, and standardization for age-expected creatinine. This 400 
“biological prior” information gave a model with better predictive performance on prospectively 401 
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collected external data than any previously published gentamicin model. Using this we developed a 402 
software tool neoGent (see Supplementary material for provisional stand-alone version, and 403 
implemented in the web TDM application TDMx (http://www.tdmx.eu/) (47)), which can be used to 404 
predict when the trough concentration will fall below 2 mg/L and so guide the dosing interval.  405 
Furthermore, peak concentration or AUC(0-24) from any post-dose sample can also be predicted with 406 
little bias. 407 
 408 
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Tables and figures 553 
 554 
Table 1: A summary of demographics and dosing 555 
 Model-building dataset Evaluation dataset 
n 205 163 
weight (g) a 2.12 (0.53-5.05) 2.03 (0.48-5.05) 
gestational age (weeks) a 34.0 (23.3-42.1) 34.3 (23.9-42.3) 
postnatal age (days) a 5.4 (1-66) 6 (1-78) 
postmenstrual age (weeks) a 33.0 (23.3-43.8) 34.9 (24-43.3) 
females (%) 89 (43%) 68 (41.7%) 
gentamicin samples per patient b 6.5 3.0 
gentamicin concentration (mg/L) a 3.4 (0.3-37.6) 1.0 (0.1-13.2) 
time after the dose (h) a 8.0 (0.02-54.1) 23.5 (0.08-79.7) 
occasion a 2 (1-22) 2 (1-7) 
Weight and gestational age are values at treatment initiation, the rest are values at time of gentamicin 556 
sampling/dosing; an occasion was defined as a dose with subsequent gentamicin samples taken; day 557 
of birth was defined as day 1; amedian (range); bmean 558 
  559 
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Table 2: Final parameter estimates from NONMEM output file and from the bootstrap analysis 560 
 Parameters from the final model Bootstrap analysis 
mean SE %CV η-shrinkage median 2.5%ile 97.5%ile 
CL (L/h/70kg) 6.21 0.30 - - 6.14 5.47 6.75 
θ_SCr -0.13 0.055 - - -0.13 -0.25 -0.03 
PNA50 (days) 1.70 0.30 - - 1.68 1.15 2.30 
V (L/70kg) 26.5 1.11 - - 26.3 23.6 28.4 
Q (L/h/70kg) 2.15 0.32 - - 2.19 1.68 3.25 
V2 (L/70kg) 21.2 1.50 - - 20.9 17.9 24.2 
Q2 (L/h/70kg) 0.27 0.047 - - 0.28 0.19 0.38 
V3 (L/70kg) 148 52.0 - - 152 65.2 534 
IIV on CL 0.175 0.038 41.8 6.9 0.170 0.104 0.254 
IIV on V 0.112 0.032 33.5 15.2 0.113 0.057 0.190 
covariance CL-V 0.116 0.030 - - 0.115 0.060 0.184 
IIV on V2 0.132 0.060 36.3 57.8 0.117 0.023 0.281 
IIV on V3 0.177 0.216 42.1 85.0 0.114 0.00002 4.18 
inter-occasion variability 0.014 0.007 11.8 - 0.013 0.001 0.029 
residual error (proportional) 0.036 0.006 19.0 - 0.036 0.025 0.049 
residual error (additive) 0.016 0.007 - - 0.015 0.000002 0.032 
CL is clearance, V is volume of distribution, Q is inter-compartmental CL, IIV is inter-individual 561 
variability, SE is standard error obtained with NONMEM 7.3 covariance step, CV is coefficient of 562 
variation. 563 
 564 
  565 
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Table 3: Summary of external evaluation with the evaluation dataset 566 
dataset Limit = 1 mg/L Limit = 2 mg/L PE (mg/L) MPE 
(mg/L) 
RMSE 
(mg/L) n correct 
(%) 
OP UP n correct 
(%) 
OP UP 
paired + 
unpaired 
214/254 
(84.3) 
20 20 242/254 
(95.3) 
10 2 0.0004 (-1.07, 
0.84) 
0.007 0.45 
paired: 
study≥1mg/L 
53/57 
(93.0) 
3 1 56/57 
(98.2) 
1 0 -0.04 (-0.57, 
0.70) 
-0.03 0.32 
paired: 
study≥2mg/L 
31/33 
(93.9) 
2 0 33/33 (100) 0 0 -0.08 (-0.50, 
0.74) 
-0.05 0.35 
paired: 
study≥3mg/L 
19/20 
(95.0) 
0 1 20/20 (100) 0 0 -0.06 (-0.56, 
0.82) 
-0.02 0.42 
unpaired 136/161 
(84.5) 
14 11 155/161 
(96.3) 
5 1 0.02 (-1.11, 
0.70) 
-0.001 0.43 
XV: paired: 
study≥3mg/L 
478/502 
(95.2) 
12 12 460/502 
(91.6) 
21 21 -0.04 (-1.77, 
3.03) 
0.03 1.28 
XV: peaks a - - - - - - 0.16 (-4.76, 
5.01) 
0.19 2.55 
AUC(0-t) a - - - - - - 10.8 (-24.9, 
62.2) b 
14.5 b 30.2 b 
Correct indicates that the predicted trough concentration agrees with the measured concentration (is 567 
above/below the limit); OP is overprediction, UP is underprediction; PE is prediction error (median 568 
(95% confidence interval)), MPE is mean prediction error, RMSE is root mean square error, XV is 569 
cross-validation. Except a  all results refer to trough prediction evaluation. b in mg h/L. 570 
 571 
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Figure legends 573 
 574 
Figure 1: Observed versus population predicted gentamicin serum concentrations (top left for the 575 
model-building dataset and bottom left for the evaluation dataset) and conditional weighted residuals 576 
versus time after dose (top right for the model-building dataset and bottom right for the evaluation 577 
dataset).  578 
 579 
Figure 2: Visual predictive check of 1000 simulated concentration-time datasets from the final model, 580 
using the model-building dataset (left) and the evaluation dataset (right). Points are the observations, 581 
black lines are the 2.5th, 50th, and 97.5th percentiles, and the shaded areas are the 95% confidence 582 
intervals of the corresponding predicted gentamicin concentrations.  583 
 584 
Figure 3: Comparison of predictive performance of the developed model (shaded box plot) and 585 
previously published neonatal gentamicin PK models. 586 
 587 
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 589 
Figure 1: Observed versus population predicted gentamicin serum concentrations (top left for the 590 
model-building dataset and bottom left for the evaluation dataset) and conditional weighted residuals 591 
versus time after dose (top right for the model-building dataset and bottom right for the evaluation 592 
dataset).  593 
 594 
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 596 
Figure 2: Visual predictive check of 1000 simulated concentration-time datasets from the final model, 597 
using the model-building dataset (left) and the evaluation dataset (right). Points are the observations, 598 
black lines are the 2.5th, 50th, and 97.5th percentiles, and the shaded areas are the 95% confidence 599 
intervals of the corresponding predicted gentamicin concentrations.  600 
 601 
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Figure 3: Comparison of predictive performance of the developed model (shaded box plot) and 604 
previously published neonatal gentamicin PK models. 605 
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